PETS - NASDAQ
PetMed Express, Inc.
$2.37
+0.0000%PetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, and other pet supplies. It sells its products through its Internet website; mobile app; telephone contact center; and direct mail/print, which includes brochures and postcards, as well as television advertising under the 1-800-PetMeds and PetMeds brands. PetMed Express, Inc. was incorporated in 1996 and is headquartered in Delray Beach, Florida.
At a Glance
Live SnapshotPetMed Express, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Moderate margins typical of competitive industries. Monitor for pricing pressure or rising costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
PetMed Express, Inc. Income Statement
PETS • NASDAQ
| PetMed Express, Inc. Income Statement | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | Mar 2009 | Mar 2008 | Mar 2007 | Mar 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
227M | 274.1M | 256.6M | 273.4M | 303.6M | 284.1M | 283.4M | 273.8M | 249.2M | 234.7M | 229.4M | 233.4M | 227.8M | 238.3M | 231.6M | 238.3M | 219.4M | 188.3M | 162.2M | 137.6M | |
GROSS PROFIT | ||||||||||||||||||||
(157.8M) | (196.4M) | (185.8M) | (198.1M) | (219.3M) | (202.9M) | (188.1M) | (176M) | (169.9M) | (158.4M) | (153.1M) | (155.8M) | (150.7M) | (158.1M) | (147.7M) | (146.4M) | (134.1M) | (114.1M) | (97.7M) | (83.2M) | |
69.1M | 77.7M | 71M | 75.3M | 84.3M | 81.2M | 95.3M | 97.8M | 79.3M | 76.3M | 76.3M | 77.6M | 77.1M | 80.2M | 84M | 91.9M | 85.3M | 74.2M | 64.6M | 54.3M | |
OPERATING INCOME | ||||||||||||||||||||
(70.7M) | (84.7M) | (64.7M) | (49.6M) | (53.8M) | (50.3M) | (49.1M) | (45.7M) | (41.8M) | (43.9M) | (46.9M) | (49.4M) | (50.1M) | (54.1M) | (50.9M) | (51.3M) | (51.1M) | (46.2M) | (43.1M) | (36.2M) | |
(62.4M) | (79.8M) | (68.9M) | (49.6M) | (49.9M) | (48M) | (46.9M) | (43.5M) | (40.5M) | (43.1M) | (46.3M) | (48.5M) | (49M) | (52.7M) | (49.6M) | (50M) | (50.3M) | (45.6M) | (42.5M) | (35.6M) | |
-1.5M | -7M | 6.6M | 25.7M | 30.5M | 31M | 46.2M | 52.1M | 37.5M | 32.4M | 27.6M | 28.2M | 27M | 26M | 33M | 40.5M | 34.2M | 28M | 21.5M | 18.1M | |
PRE-TAX INCOME | ||||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (1.2M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 511K | 450K | 335K | -896K | 1.7M | 1.9M | 658K | 141K | 190K | 184K | 185K | 306K | 288K | 381K | 196K | 1.1M | 1.8M | 0.0 | 0.0 | |
(8.2M) | (4.9M) | -4.2M | (0.0) | (3.9M) | (2.3M) | (1.1M) | (995K) | (300K) | (63K) | (1K) | -4K | -5K | (1.4M) | (1.4M) | (1.3M) | (814.5K) | (590K) | (530.4K) | (544.5K) | |
943K | 689K | 894K | 1.4M | 419K | 2.9M | 2.9M | 1.7M | 441K | 179K | 185K | 181K | 301K | 349K | 253K | 200K | 1.5M | 2.4M | 1.7M | 890K | |
-587K | -6.3M | 7.4M | 27.1M | 31M | 33.9M | 49.1M | 53.8M | 37.9M | 32.6M | 27.8M | 28.4M | 27.3M | 26.4M | 33.3M | 40.7M | 35.7M | 30.4M | 23.2M | 19M | |
NET INCOME | ||||||||||||||||||||
(5.7M) | (1.2M) | (2.3M) | (6M) | (7M) | (8M) | (11.4M) | (16.5M) | (14.1M) | (12M) | (10.3M) | (10.4M) | (10.1M) | (9.7M) | (12.4M) | (14.7M) | (12.7M) | (10.4M) | (8.8M) | (7M) | |
-6.3M | -7.5M | 5.1M | 21.1M | 23.9M | 25.9M | 37.7M | 37.3M | 23.8M | 20.6M | 17.5M | 18M | 17.2M | 16.7M | 20.9M | 26M | 23M | 20M | 14.4M | 12.1M |
SEC Filings
PETS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2025 Q4 Q4 | February 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 23, 2026 | January 21, 2026 | 2026 | |
8-K/A 8-K/A 2025 (Amended) N/A | December 29, 2025 | December 08, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | December 19, 2025 | September 30, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | December 19, 2025 | June 30, 2025 | 2025 | |
DEF 14A DEF 14A 2026 N/A | December 10, 2025 | January 21, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 09, 2025 | December 08, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 26, 2025 | November 26, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 12, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 21, 2025 | October 19, 2025 | 2025 |
Related Guides
Continue your PETS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.